Page last updated: 2024-10-16

adenine and MS (Multiple Sclerosis)

adenine has been researched along with MS (Multiple Sclerosis) in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Feng, X1
Hou, H1
Zou, Y1
Guo, L1
Savic, RM1
Novakovic, AM1
Ekblom, M1
Munafo, A1
Karlsson, MO1
Heidari, A1
Behmanesh, M1
Sahraian, MA1
Meshkani, R1
Darvish, H1
Najmabadi, H1
Ohadi, M1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase III, Randomized, Double-blind, Three-arm, Placebo-controlled, Multi-center Study to Evaluate the Safety and Efficacy of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)[NCT00213135]Phase 31,326 participants (Actual)Interventional2005-04-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Annualized Qualifying Relapse Rate

A qualifying relapse was defined as an increase of 2 points in at least one functional system of the expanded disability status scale (EDSS) or an increase of 1 point in at least two functional systems (excluding changes in bowel or bladder function or cognition) in the absence of fever, lasting for at least 24 hours and to have been preceded by at least 30 days of clinical stability or improvement. Expanded disability status scale (EDSS) assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to multiple sclerosis [MS]) was calculated. The annualized relapse rate for each treatment group was calculated as the total number of confirmed relapses divided by the total number of days on study multiplied by 365.25. (NCT00213135)
Timeframe: Week 96

Interventionrelapses per year (Number)
Cladribine 5.25 mg/kg0.15
Cladribine 3.5 mg/kg0.14
Placebo0.33

Percentage of Relapse-free Participants

A qualifying relapse was defined as an increase of 2 points in at least one functional system of the EDSS or an increase of 1 point in at least two functional systems (excluding changes in bowel or bladder function or cognition) in the absence of fever, lasting for at least 24 hours and to have been preceded by at least 30 days of clinical stability or improvement. Expanded disability status scale (EDSS) assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated. (NCT00213135)
Timeframe: Week 96

Interventionpercentage of participants (Number)
Cladribine 5.25 mg/kg78.9
Cladribine 3.5 mg/kg79.7
Placebo60.9

Time to Disability Progression

Time to disability progression was defined as the time to a sustained increase in EDSS score of at least 1 point if baseline EDSS score between 0.5 and 4.5 inclusively, or at least 1.5 points if the baseline EDSS score was 0, or at least 0.5 point if the baseline EDSS score was at least 5, over a period of at least three months. Expanded disability status scale (EDSS) assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated. Tenth Percentile of time to sustained increase in EDSS score was reported using Kaplan-Meier survival curve. (NCT00213135)
Timeframe: Baseline up to Week 96

Interventionmonths (Number)
Cladribine 5.25 mg/kg13.6
Cladribine 3.5 mg/kg13.6
Placebo10.8

Mean Number of Combined Unique (CU) Lesions, Active Time Constant 2 (T2) Lesions, and Active Time Constant 1 (T1) Gadolinium-Enhanced (Gd+) Lesions Per Participant Per Scan

Mean Number of CU lesions, active T2 lesions, and active T1 Gd+ lesions were measured by using magnetic resonance imaging (MRI) scans. (NCT00213135)
Timeframe: Week 96

,,
Interventionlesions (Least Squares Mean)
CU lesionsActive T1 Gd+ lesionsActive T2 lesions
Cladribine 3.5 mg/kg0.430.120.38
Cladribine 5.25 mg/kg0.380.110.33
Placebo1.720.911.43

Trials

1 trial available for adenine and MS (Multiple Sclerosis)

ArticleYear
Population Pharmacokinetics of Cladribine in Patients with Multiple Sclerosis.
    Clinical pharmacokinetics, 2017, Volume: 56, Issue:10

    Topics: Adenine; Administration, Intravenous; Administration, Oral; Adult; Aged; Cladribine; Double-Blind Me

2017

Other Studies

2 other studies available for adenine and MS (Multiple Sclerosis)

ArticleYear
Defective autophagy is associated with neuronal injury in a mouse model of multiple sclerosis.
    Bosnian journal of basic medical sciences, 2017, May-20, Volume: 17, Issue:2

    Topics: Adenine; Animals; Apoptosis; Autophagy; Beclin-1; Caspase 3; Disease Models, Animal; Encephalomyelit

2017
The human caveolin 1 gene upstream purine complex and neurodegeneration--a common signature.
    Journal of neuroimmunology, 2011, Volume: 236, Issue:1-2

    Topics: Adenine; Case-Control Studies; Caveolin 1; Guanine; Haplotypes; Humans; Multiple Sclerosis; Neurodeg

2011